[ * ] = CERTAINCONFIDENTIALINFORMATIONCONTAINEDINTHISDOCUMENT,MARKEDBYBRACKETS,HASBEENOMITTEDANDFILEDSEPARATELYWITHTHE SECURITIESAND EXCHANGE COMMISSIONPURSUANTTO RULE 24B-2OFTHE SECURITIES EXCHANGE ACTOF 1934,ASAMENDED.
Exhibit 10.42
Robert J. Beall, Ph.D.
Cystic Fibrosis Foundation Therapeutics, Inc.
6931 Arlington Road
Bethesda, MD 20814
Dear Dr.Beall:
The purpose of this letter agreement is to amend the Study Funding Agreement, dated June 17, 2003, between the undersigned parties (the “Agreement”). By signing below, the undersigned parties agree to hereby amend the Agreement as follows:
| 1. | In Section 8.1(c) of the Agreement,[ * ]shall be replaced with[ * ]. |
All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect.
HOLLIS-EDEN PHARMACEUTICALS, INC. | ||
By: | /s/ E. Loumeau | |
Eric J. Loumeau Vice President, General Counsel | ||
| Agreed to and Acknowledged by: | ||
| CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | ||
| By: | /s/ R. Beall | |
Robert J. Beall, Ph.D. President and CEO | ||
